Premature atherosclerosis is associated with hypovitaminosis d and angiotensin-converting enzyme inhibitor non-use in lupus patients

American Journal of the Medical Sciences

Volumn 344, Issue 4, 2012, Pages 268-273

  Ravenell, Roneka L ^a   Kamen, Diane L ^a   Spence, J David ^b   Hollis, Bruce W ^a   Fleury, Thomas J ^a   Janech, Michael G ^a   Almeida, Jonas S ^c   Shaftman, Stephanie R ^a   Oates, Jim C ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Atherosclerosis; Hypercholesterolemia; Systemic lupus erythematosus; Vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AFRICAN AMERICAN; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRAMINGHAM RISK SCORE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD; MEDICINE; PREDICTIVE VALUE; RISK FACTOR; RISK REDUCTION; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 84866943488     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31823fa7d9     Document Type: Article

References (31)

1. Urowitz MB, Ibanez D, Cladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007;34:70-5.
2. Scalzi LV, Hollenbeak CS, Wang L. Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:2767-75.
3. Rhew EY, McPherson DD, Dyer AR, et al. Endothelial dysfunction (ED) correlates with plaque burden in systemic lupus erythematosus (SLE) women. San Diego, CA: American College of Rheumatology National Meeting; 2005.
4. Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003;115(suppl 8A): 99S-106S.
5. Giovannucci E, Liu Y, Hollis BW, et al. 25-Hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med 2008;168:1174-80.
6. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 2009;94:4023-30.
7. Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006;5:114-7.
8. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfiinction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94: 258-65.
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
10. Spence JD. Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol 2002;89:10B-5B; discussion 5B-6B.
11. Spence JD, Eliasziw M, DiCicco M, et al. Carotid plaque area: A tool for targeting and evaluating vascular preventive therapy. Stroke 2002; 33:2916-22.
12. Johnsen SH, Mathiesen EB. Carotid plaque compared with intimamedia thickness as a predictor of coronary and cerebrovascular disease. Curr Cardiol Rep 2009;11:21-7.
13. Johnsen SH, Mathiesen EB, Joakimsen O, et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: A 6-year follow-up study of 6226 persons: the Tromso Study. Stroke 2007;38:2873-80.
14. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
15. Spence JD, Hackam DG. Treating arteries instead of risk factors: A paradigm change in management of atherosclerosis. Stroke 2010;41:1193-9.
16. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005;142:953-62.
17. Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus 1999;8:632-7.
18. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease, guideline 4: estimation of GFR. Am J Kidney Dis 2002;39:S76-l10.
19. Hollis BW. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin Chem 2000;46:1657-61.
20. Bishop CM. Pattern recognition and machine learning. New York: Springer; 2006. p. 124-7.
21. Almeida JS. BioinformaticStation.org. Accessed July 15, 2010.
22. Oates JC, Varghese S, Bland AM, et al. Prediction of urinary protein markers in lupus nephritis. Kidney Int 2005;68:2588-92.
23. Almeida JS. Predictive non-linear modeling of complex data by artificial neural networks. Curr Opin Biotechnol 2002;13:72-6.
24. Hollis BW. Circulating 25-hydroxyvitamin d levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005;135:317-22.
25. Al-Shali K, House AA, Hanley AJ, et al. Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis 2005;178:319-25.
26. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 145-53.
27. Nickenig G, Harrison DG. The AT(l)-type angiotensin receptor in oxidative stress and atherogenesis. Part I: Oxidative stress and atherogenesis. Circulation 2002;105:393-6.
28. Wu PW, Rhew EY, Dyer AR, et al. 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Care Res 2009;61:1387-95.
29. Mok CC, Birmingham DJ, Leung HW, et al. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis [published online ahead of print June 29, 2011]. Rheumatology (Oxford), doi: 10.1093/rheumatology/ker212.
30. Bair T, Muhlestein JBM, May HT, et al. Supplementing deficient vitamin D levels is associated with reduced cardiovascular risk. American College of Cardiology Annual Meeting; March 15; Atlanta, GA 2010; Presentation number 1186-111.
31. Cardus A, Panizo S, Encinas M, et al. 1,25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009;204:85-9.